NEW YORK, NY--(Marketwire - Mar 12, 2013) - Nuvilex, Inc. (
Remember not so long ago when every science related conversation seemed to weave its way into a conversation about stem cells? Back around 2007, there was a real phenomenon going on among biotechnology companies that had anything at all to do with stem cells, and now six years later with more research in the books, that enthusiasm has waned a bit.
Still, stem cell treatments are being developed for many ailments including heart damage, arthritis, "joint" injuries, neurologic diseases such as Parkinson's, Alzheimer's, ALS, dementia, and even wound repair, among a host of others. However, progress with the development of stem cell-based therapies has been tempered somewhat, largely because of the characteristics of the stem cells themselves.
The way the process is supposed to work is that stem cells or other therapeutic cells are implanted or injected into a patient's body to enable the cells' therapeutic action. This therapeutic action can be achieved by the cells producing a "beneficial" healing factor, or by "signaling" to other cells and stimulating healing.
Clear the Hurdles - Reignite the Phenomenon
However, industry leaders have consistently found a number of hurdles limiting the success of stem cell treatments including; immune system attacks on the transplanted cells, migration of the cells after transplantation, formation of abnormal growths (including tumors) after such migration, problems with long-term storage of the cells for later use, and problems with the use of the cells inside bioreactors.
With recent estimates predicting the global market for stem cells and stem cell products reaching almost $6.6-billion by 2016, the research continues. Companies like StemCells, Inc., Aastrom Biosciences, Inc., BioTime, Inc., International Stem Cell Corp. and Advanced Cell Technology among many others are hard at work in the sector trying to solve the roadblocks that keep the FDA from approving any stem cell treatment to date.
Meanwhile, Nuvilex, a biotech headquartered in Silver Spring, Maryland, is currently in negotiations with biotechnology and pharmaceutical entities that wish to examine the employment of Nuvilex's living cell encapsulation technology, or Cell-in-a-Box™, in the development of treatments for various diseases that would utilize stem cells.
What is Cell-in-a-Box? Could this living cell encapsulation technology be the silver bullet to get many stem cell companies through some of the roadblocks that have plagued their success?
Read the full Feature News Article at www.stockhousegroup.com/features
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.
Contact Information:
Contact:
Stock House Group
646-397-4020